Novo Nordisk and Mylan Settle Ozempic, Wegovy Patent Battles

Mylan Pharmaceuticals Inc. and Novo Nordisk A/S settled a patent lawsuit and validity challenge linked to Novo’s blockbuster weight-loss and diabetes drugs Ozempic and Wegovy.

The pharmaceutical companies asked the Patent Trial and Appeal Board to terminate Mylan’s challenge to Novo US Patent No. 10,335,462, in a motion filed Oct. 4, two days after the parties told the US District Court for the District of Delaware that they’d settled Novo’s lawsuit accusing Mylan of infringing numerous patents to create a generic version of Ozempic.

Novo sued Mylan in 2022 in a West Virginia federal court—one of a flurry of ...